论文部分内容阅读
大量实验材料证明,使用放射增敏剂醚醇硝唑(misonidazole)可以增加乏氧肿瘤细胞对射线的敏感性,从而提高对肿瘤治疗的效果。本文报告将此药用于12例中晚期癌症病人(肺鳞癌8例,转移性肺鳞癌1例,小细胞未分化肺癌1例,恶性黑色素瘤2例)的观察结果。患者一般情况中等,无神经系统疾患。给药方法:口服醚醇硝唑1.2g,装于胶囊内,每周二次,共5周。黑色素瘤病人加用10～20%醚醇硝唑溶液10～20ml局部涂布3次。临床应用结果:对肺鳞癌病人有一定效益,特别是对肺不张的复张所需的累积照射剂量明显减少,与对照组比较P<0.01。一例黑色素瘤病人的疗效显著。醚醇硝唑的毒性作用不明显,有轻微的恶心,一过性的食欲减退,占服药病人的5/11,未见神经系统并发症。病人服药后采耳血,用高效液相色谱法测定血中醚醇硝唑浓度(平均高峰值39μg/ml,峰时2.5h),据此来调整病人的照射时间,以期取得最佳放射增敏效果。
Numerous experimental materials have demonstrated that the use of the radiosensitizer misonidazole increases the radiosensitivity of hypoxic tumor cells and enhances the effect on tumor therapy. This article reports the drug used in 12 cases of advanced cancer patients (squamous cell carcinoma of the lung in 8 cases, metastatic squamous cell carcinoma in 1 case, small cell undifferentiated lung cancer in 1 case, 2 cases of malignant melanoma) observed. In general, patients with no neurological disorders. Method of administration: oral ether metronidazole 1.2g, packed in capsules, twice a week for a total of 5 weeks. Melanoma patients plus 10 to 20% ether metronidazole solution 10 ~ 20ml topical coating 3 times. Clinical application results: The patients with squamous cell lung cancer have some benefits, especially for the cumulative exposure dose required for atelectasis of atelectasis decreased significantly compared with the control group P <0.01. A case of melanoma patients have a significant effect. Ethanol metronidazole toxic effects are not obvious, a slight nausea, transient loss of appetite, taking the medication of patients 5/11, no neurological complications. After taking the medicine, the patients took the blood of ear and measured the concentration of metronidazole in blood (mean peak value 39μg / ml, peak time 2.5h) by HPLC, and adjusted the patient’s irradiation time to get the best radiation Sensitive effect.